Abstract
Fas and Fas ligand (FasL) are the main genes that control cell death in the immune system. Indeed, they are crucial for the regulation of T lymphocyte homeostasis because they can influence cell proliferation. A strong debate exists on the importance of Fas/FasL system during HIV infection, which is characterized by the loss of CD4+ T cells directly, or indirectly, caused by the virus. To investigate whether the genetic background of the host plays a role in the immunoreconstitution, we studied the influence of different Fas and FasL polymorphisms on CD4+ T lymphocyte count and plasma viral load following initiation of highly active antiretroviral therapy (HAART) in drug-naïve HIV+ patients. We studied 131 individuals, who were compared to 136 healthy donors. Statistical analysis was performed by using X 2 test, Fischer's Exact Test, and analysis for repeated measurements. The group of HIV+ patients had an unexpected lower frequency of FasLnt169 polymorphism (delT allele) than healthy controls (p=0.039). We then observed no significant differences in the immune reconstitution, in terms of CD4+ T cell increase, when the influence of single alleles of the gene Fas or FasL was considered. However, the combination of some polymorphisms of Fas or FasL significantly influenced CD4+ T cell production and viral load decrease, showing that these genes can play a role in the immunoreconstitution triggered by antiretroviral therapy.
Abbreviations
- NRTI:
-
nucleosidic reverse transcriptase inhibitors
- NNRTI:
-
non-nucleosidic reverse transcriptase inhibitors
- PI:
-
protease inhibitors
- HIV:
-
human immunodeficiency virus
References
Bahr GM, Capron A, Dewulf J, Nagata S, Tanaka M, Bourez JM, Mouton Y (1997) Elevated serum level of Fas ligand correlates with the asymptomatic stage of human immunodeficiency virus infection. Blood 90:896–898
Bohler T, Baumler C, Herr I, Groll A, Kurz M, Debatin KM (1997a) Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Pediatr Infect Dis J 16:754–759
Bohler T, Nedel S, Debatin KM (1997b) CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Pediatr Res 41:878–885
Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R (2000) Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J Rheumatol 27:2397–2405
Boudet F, Lecoeur H, Gougeon ML (1996) Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+T lymphocytes during HIV infection. J Immunol 156:2282–2293
Cossarizza A, Stent G, Mussini C, Paganelli R, Borghi V, Nuzzo C, Pinti M, Pedrazzi J, Benatti F, Esposito R, Rosok B, Nagata S, Vella S, Franceschi C, De Rienzo B (2000) Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. AIDS 14:345–355
Dockrell DH (2001) Apoptotic cell death in the pathogenesis of infectious diseases. J Infect 42:227–234
Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, Brookes AJ (2000) apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum Genet 107:391–396
Huang QR, Manolios N (2000) Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 32:126–130
Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582
Huang QR, Danis V, Lassere M, Edmonds J, Manolios N (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38:645–651
Jimenez A, Molero L, Jimenez A, Castanon S, Subira D, De Gorgolas M, Fedz Guerrero M, Garcia R (2002) Role of antiretroviral regimes in HIV-1 patients in reducing immune activation. Immunology 106:80–86
Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, Tschopp J (2000) The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 10:640–648
Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA (1995) Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 181:2029–2036
Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis–immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221–253
Li-Weber M, Laur O, Dern K, Krammer PH (2000) T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB. Eur J Immunol 30:661–670
Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC, Kumar R (1996) Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. J Biol Chem 271:30354–30359
Marusawa H, Hijikata M, Watashi K, Chiba T, Shimotohno K (2001) Regulation of Fas-mediated apoptosis by NF-kappaB activity in human hepatocyte derived cell lines. Microbiol Immunol 45:483–489
Mueller YM, De Rosa SC, Hutton JA, Witek J, Roederer M, Altman JD, Katsikis PD (2001) Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. Immunity 15:871–882
Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33:29–55
Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A (2003) MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696–1698
Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S (1994) Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 84:2622–2631
Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD (2003) Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 138:620–626
Pinti M, Nasi M, Moretti L, Mussini C, Petrusca D, Esposito R, Cossarizza A (2000) Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR. Ann N Y Acad Sci 926:46–51
Pinti M, Troiano L, Nasi M, Moretti L, Monterastelli E, Mazzacani A, Mussi C, Ventura P, Olivieri F, Franceschi C, Salvioli G, Cossarizza A (2002) Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 9:431–438
Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J (1995) Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol 14:931–937
Salmon M, Pilling D, Borthwick NJ, Viner N, Janossy G, Bacon PA, Akbar AN (1994) The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J Immunol 24:892–899
Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF (2000) Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 88:333–347
Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330
Wajant H, Pfizenmaier K, Scheurich P (2003) Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 14:53–66
Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH (1995) Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497–500
Acknowledgements
We acknowledge Professor Judith A. Aberg (Washington University, St. Louis, MO, USA) and Professor Domenico Lio (University of Palermo, Italy) for helpful comments and critical reading of the manuscript. Supported by Istituto Superiore di Sanità (Programma Nazionale di Ricerca sull'AIDS, grant 40F.30, to A.C.). All the experiments comply with current Italian laws.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nasi, M., Pinti, M., Bugarini, R. et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients. Immunogenetics 57, 628–635 (2005). https://doi.org/10.1007/s00251-005-0031-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-005-0031-z